{"disease":{"id":"pleural-mesothelioma","name":"pleural mesothelioma"},"drugs":{"marketed":[{"drug_id":"nivolumab","indication_name":"Unresectable advanced or recurrent malignant pleural mesothelioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"ipilimumab","indication_name":"Unresectable advanced or recurrent malignant pleural mesothelioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yervoy","generic_name":"ipilimumab","company_name":"Bristol-Myers Squibb","drug_phase":"discontinued","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody","quality_score":0,"revenue":"2900","mechanism":"Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells."},{"drug_id":"pemetrexed-dipotassium","indication_name":"Initial treatment of malignant pleural mesothelioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PEMETREXED DIPOTASSIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Folate Analog Metabolic Inhibitor [EPC]","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1789844","indication_name":"Unresectable Malignant Pleural Mesothelioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IPILIMUMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CTLA-4-directed Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"pemetrexed-disodium","indication_name":"Malignant Pleural Mesothelioma - Initial Treatment with Cisplatin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PEMETREXED DISODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"yervoy","indication_name":"Unresectable advanced or recurrent malignant pleural mesothelioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yervoy","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"","quality_score":16,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05910112","title":"Prospective Data Collection on Clinical, Radiological and Patient Reported Outcomes After Pleural Intervention","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT00242723","title":"Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining","phase":"","overall_status":"RECRUITING","enrollment_count":1310,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06097728","title":"MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":825,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT01843374","title":"Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":571,"lead_sponsor_name":"MedImmune LLC","has_results":true},{"nct_id":"NCT02214134","title":"SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access","phase":"","overall_status":"COMPLETED","enrollment_count":539,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":false},{"nct_id":"NCT05042557","title":"Real World Study of MPM in China","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT03762018","title":"BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":401,"lead_sponsor_name":"ETOP IBCSG Partners Foundation","has_results":false},{"nct_id":"NCT05107674","title":"A Study of NX-1607 in Adults With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":345,"lead_sponsor_name":"Nurix Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07449624","title":"From Presentation to Diagnosis: Patterns of Pleural Effusion","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Mansoura University Hospital","has_results":false},{"nct_id":"NCT07277413","title":"A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"IDEAYA Biosciences","has_results":false},{"nct_id":"NCT06535607","title":"Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":257,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06581549","title":"Immune Microenvironment and Gene Expression Profiling in Mesothelioma","phase":"","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Istituto Oncologico Veneto IRCCS","has_results":false},{"nct_id":"NCT04334759","title":"DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":214,"lead_sponsor_name":"PrECOG, LLC.","has_results":false},{"nct_id":"NCT05308966","title":"Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)","phase":"","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"Groupe Francais De Pneumo-Cancerologie","has_results":false},{"nct_id":"NCT04843007","title":"Alvopem® (Pemetrexed) Safety Assessment","phase":"","overall_status":"COMPLETED","enrollment_count":199,"lead_sponsor_name":"NanoAlvand","has_results":true},{"nct_id":"NCT05278975","title":"Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":186,"lead_sponsor_name":"RS Oncology LLC","has_results":false},{"nct_id":"NCT03537833","title":"Association Between Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed","phase":"","overall_status":"COMPLETED","enrollment_count":172,"lead_sponsor_name":"CHU de Reims","has_results":false},{"nct_id":"NCT05655078","title":"Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma","phase":"NA","overall_status":"RECRUITING","enrollment_count":148,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT02991482","title":"PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":144,"lead_sponsor_name":"ETOP IBCSG Partners Foundation","has_results":true},{"nct_id":"NCT05337735","title":"A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":140,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03074513","title":"Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":133,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06362369","title":"A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":126,"lead_sponsor_name":"7 Hills Pharma, LLC","has_results":false},{"nct_id":"NCT01064648","title":"Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":117,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04775446","title":"Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy","phase":"","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"Centre Hospitalier Intercommunal Creteil","has_results":false},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04914897","title":"A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":106,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT06946498","title":"First Local Anaesthesia Thoracoscopy for Pleural Effusion Diagnosis.","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"National and Kapodistrian University of Athens","has_results":false},{"nct_id":"NCT02761863","title":"Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural Mesothelioma","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Ain Shams University","has_results":false},{"nct_id":"NCT04177953","title":"Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":92,"lead_sponsor_name":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","has_results":false},{"nct_id":"NCT00738582","title":"An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Morphotek","has_results":true},{"nct_id":"NCT04042480","title":"A Study of SGN-CD228A in Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":88,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT04491942","title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":74,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05461430","title":"Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)","phase":"","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Travera Inc","has_results":false},{"nct_id":"NCT06790082","title":"The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Aalborg University Hospital","has_results":false},{"nct_id":"NCT04480372","title":"SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Swiss Cancer Institute","has_results":false},{"nct_id":"NCT05228015","title":"Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":67,"lead_sponsor_name":"Ikena Oncology","has_results":false},{"nct_id":"NCT03054298","title":"CAR T Cells in Mesothelin Expressing Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"University of Pennsylvania","has_results":true},{"nct_id":"NCT02399371","title":"Pembrolizumab in Treating Patients With Malignant Mesothelioma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":65,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT07411144","title":"Gemcitabine as Maintenance Treatment for Diffuse Pleural Mesothelioma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"National Cancer Institute, Egypt","has_results":false},{"nct_id":"NCT01675765","title":"Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Aduro Biotech, Inc.","has_results":true},{"nct_id":"NCT06416930","title":"Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":59,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT03907852","title":"Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":57,"lead_sponsor_name":"TCR2 Therapeutics","has_results":false},{"nct_id":"NCT00652574","title":"Dasatinib in Resectable Malignant Pleural Mesothelioma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02899195","title":"Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"PrECOG, LLC.","has_results":true},{"nct_id":"NCT06637345","title":"Identification of Prognostic and Predictive Biomarkers of Toxicity in Patients With Malignant Pleural Mesothelioma and Treated With High Doses of Radiotherapy (MESORTIBO)","phase":"","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"Centro di Riferimento Oncologico - Aviano","has_results":false},{"nct_id":"NCT03126630","title":"Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":49,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04324437","title":"eRAPID: Online Symptom Reporting in Lung Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"University of Leeds","has_results":false},{"nct_id":"NCT03213301","title":"Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Swiss Cancer Institute","has_results":false},{"nct_id":"NCT01265433","title":"Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Sellas Life Sciences Group","has_results":true},{"nct_id":"NCT05077111","title":"A Comparative Study Between Regional Anesthesia in Thoracoscopes and the Conventional General Anesthesia","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Mohamed Reda Ashour","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}